Labelling of the guanylate cyclase activator cinaciguat (BAY 58‐2667) with carbon‐14, tritium and stable isotopes

For studies of pharmacokinetics and drug metabolism of the new soluble guanylate cyclase activator cinaciguat (BAY 58‐2667) the ¹⁴C‐labelled compound was synthesized. The tritiated compound was required to elucidate the mode of action and the stable labelled compound was required for bio‐analytical studies by quantitative mass spectrometry as well. Two radiosyntheses are described with different formation of the labelled intermediate 1‐(chloro[¹⁴C]methyl)‐4‐(2‐phenylethyl)benzene. The first one started with ¹⁴C‐carboxylation of 1‐bromo‐4‐(2‐phenylethyl)benzene yielding the desired product in 5 steps. In the second synthesis intermediate 1‐(chloro[¹⁴C]methyl)‐4‐(2‐phenylethyl)benzene was formed by chloromethylation of bibenzyl with [¹⁴C]paraformaldehyde/hydrochloric acid subsequently resulting in the final product in three steps. Tritium labelling was performed by tritium exchange of the diester intermediate using an organo‐iridium catalyst and subsequent saponification. The stable labelled compound was synthesized via a convergent synthesis starting with ¹³C,¹⁵N‐cyanation of 1‐(chloromethyl)‐2‐{[4‐(2‐phenylethyl)benzyl]oxy}benzene and ¹³C‐cyanation of methyl 4‐bromobenzoate, respectively. The labelled product was obtained after 7 chemical steps. Copyright © 2010 John Wiley & Sons, Ltd.     

Synthesis of tritium and carbon‐14 labelled NNC 61‐4655: a potent dual‐acting PPARα and PPARγ agonist

The synthesis of the potent dual‐acting PPARα and PPARγ agonist NNC 61‐4655 labelled with tritium and carbon‐14 is reported. Tritium labelled NNC 61‐4655 was obtained in three steps with introduction of tritium through catalytic tritium‐halogen exchange of an aryl bromide precursor. This provided [³H]NNC 61‐4655 in 39% overall radiochemical yield with a specific activity of 49 Ci/mmol. Carbon‐14 labelled NNC 61‐4655 was obtained in five steps starting from bromo[1‐¹⁴C]acetic acid. The synthetic sequence, which included a Horner–Wadsworth–Emmons olefination and a Mitsunobu alkylation, provided [¹⁴C]NNC 61‐4655 in 33% overall radiochemical yield with a specific activity of 57.4 mCi/mmol. Copyright © 2003 John Wiley & Sons, Ltd.     

Synthesis of tritium‐labelled 3′‐azido‐3′‐deoxythymidine

New approaches to the synthesis of 3′‐azido‐3′‐deoxythymidine labelled with tritium in the heterocyclic base have been developed. With this aim, enzymatic transribosylation with [³H]thymine using the enzyme preparation from rat liver and a three‐step chemical synthesis with use of the tritium labelled precursor were studies. The enzyme preparation did not catalyse the transfer of the 3′‐azido‐3′‐deoxyribosyl fragment to the [³H]thymine residue. 5′‐O‐Benzoyl‐2,3′‐anhydrothymidine was taken as a precursor for the tritium labelling by the chemical methods. The resulting [³H]3′‐azido‐3′‐deoxythymidine was obtained with a specific radioactivity of 18.3 Ci/mmol, the tritium is located in the C‐6 position of the thymine residue. Copyright © 2003 John Wiley & Sons, Ltd.     

Synthesis of 14C‐ and 14C3‐labelled Org 37462

Org 37462 (1) is the active ingredient in Orgalutran^®, an innovative product that reduces the time of treatment in in vitro fertilization from four to less than two weeks. Org 37462 is a synthetic decapeptide containing several amino acids that are unnatural in stereochemistry and/or in structure. The synthesis, starting with a ProtectingGroup‐D‐Ala‐resin, is a typical solid state synthesis. For the conduction of several metabolism studies, Org 37462 had to be labelled with carbon 14. It was decided to label D‐3‐(2‐naphthyl)alanine, the last amino acid to be coupled to the resin. We report the synthesis of [¹⁴C]‐ and [¹⁴C₃]‐Org 37462, starting from 2‐bromo‐[¹⁴C‐methyl]‐naphthalene and [¹⁴C₂]‐tert‐butyl glycinate. Copyright © 2008 John Wiley & Sons, Ltd.     

Synthesis of tritium labelled [2′,6′]‐L‐tyrosine

The synthesis of a specifically ring labelled isotopomer of L ‐tyrosine, (L ‐Tyr), using a combination of chemical and enzymatic methods is reported. The tritium labelled [2′,6′]‐L ‐Tyr has been synthesized via catalytic exchange of phenol with tritiated water in the presence of K₂PtCl₄, reverse acid catalysed removal of tritium from the o‐ and p‐positions of phenol, and subsequent condensation of the resulting [3′,5‐³H₂]‐phenol with S‐methyl‐L ‐cysteine using the enzyme β‐tyrosinase from Citrobacter freundii. Copyright © 2004 John Wiley & Sons, Ltd.     

Syntheses of novel N‐([18F]fluoroalkyl)‐N‐nitroso‐4‐methyl‐benzenesulfonamides and decomposition studies of corresponding 19F‐ and bromo‐analogues: potential new compounds for the 18F‐labelling of radiopharmaceuticals

N‐([¹⁸F]fluoroalkyl)‐N‐nitroso‐4‐methyl‐benzensulfonamides [n‐alkyl = (?CH₂)[^18,19F]F, n=2–4)] were synthesized in radiochemical yields ranging from 75–90% to provide new secondary labelling precursors for the syntheses of ¹⁸F‐labelled compounds. Preliminary decomposition studies utilizing the corresponding non‐radioactive ¹⁹F‐compounds as well as the bromo containing analogous compounds were performed to evaluate their stability regarding temperature and basicity of the labelling medium. Furthermore, initial difficulties in labelling these compounds led to the development of a modified labelling procedure applying nearly solvent‐free conditions. Extensive decomposition experiments of the new fluoro‐ as well as the bromo‐compounds were conducted under various conditions in order to get experimental data about their stability and reactivity. As a result, different trends for the stability of the bromo as well as the fluoro compounds could be observed. Copyright © 2003 John Wiley & Sons, Ltd.     

The synthesis of a benzamidine‐containing NR2B‐selective NMDA receptor ligand labelled with tritium or fluorine‐18

A novel tritium or flourine‐18‐labelled benzamidine‐containing NR2B‐selective NMDA receptor ligand has been synthesized. This compound was designed to contain the fluoromethoxy group to allow for the synthesis of a high specific activity, fluorine‐18‐labelled PET tracer for imaging studies of the NR2B receptor. In addition to the fluorine‐18‐labelled compound, this compound was also tritium labelled. The tritiated ligand (11 Ci/mmol) was synthesized by a gas tritiation reaction of an aryl bromide precursor. The fluorine‐18 ligand (2916 Ci/mmol), which was deuterated in the fluoromethoxy group to aid in metabolic stability, was synthesized by alkylating a phenolic precursor with [¹⁸F]fluoromethylbromide‐d₂. Copyright © 2004 John Wiley & Sons, Ltd.     

Synthesis of deuterium‐labelled (−)‐galanthamine

The synthesis of deuterium‐labelled galanthamine is reported. 6‐[²H₃]methoxy‐N‐[²H₃]methyl‐(?)‐galanthamine was obtained in seven steps from galanthamine. The synthesis was carried out by selective O‐ and N‐demethylations. The [²H₃]‐N‐methyl and [²H₃]‐O‐methyl‐groups were introduced by selective aminoreduction and O‐methylation. Copyright © 2008 John Wiley & Sons, Ltd.     

Synthesis of deuterium‐, tritium‐, and carbon‐14‐labeled BILN2061, a potent hepatitis C virus protease inhibitor

Hepatitis C virus (HCV) serine protease is a target for antiviral therapy against HCV infection, a leading cause of liver transplantation in the US. BILN2061, (1S, 4R, 6S, 7Z, 14S, 18R)‐14‐cyclopentyloxycarbonylamino‐18‐[2‐(2‐isopropylamino‐thiazol‐4‐yl)‐7‐methoxyquinolin‐4‐yloxy]‐2,15‐dioxo‐3,16‐diazatricyclo[14.3.0.0^4,6]nonadec‐7‐ene‐4‐carboxylic acid, is a potent inhibitor of HCV and the first compound in this class of cyclic peptides in human trials. Here, we report the synthesis of deuterium‐labeled BILN2061 with isotopic enrichment of 99%, tritium‐labeled BILN2061 with a specific activity of 17.1 GBq/mmol, and carbon‐14‐labeled BILN2061 with a specific activity of 1.83 GBq/mmol. The isotopes were incorporated via a Hantzsch thiazole synthesis of labeled isopropyl thiourea and α‐bromoketone intermediate. The preparation of labeled isopropyl thiourea is reported. Copyright © 2005 John Wiley & Sons, Ltd.     

Synthesis of morphine‐[N‐methyl‐14C]‐6‐β‐D‐glucuronide

Protected morphine‐6‐glucuronide was converted into morphine‐[N‐methyl‐¹⁴C]‐6‐glucuronide by a three‐step procedure. Methyl (3‐pivaloylmorphin‐6‐yl 2,3,4‐tri‐O‐isobutyryl‐β‐D‐glucopyranosid)uronate was N‐demethylated by treatment with 1‐chloroethyl chloroformate to afford protected normorphine‐6‐glucuronide as its hydrochloride salt. The normorphine‐6‐glucuronide derivative was alkylated with iodomethane‐[¹⁴C] in the presence of potassium carbonate to produce C‐14 labelled protected morphine‐6‐glucuronide. Finally, hydrolysis of the protecting groups using 5% sodium hydroxide solution gave morphine‐[N‐methyl‐¹⁴C]‐6‐β‐D‐glucuronide with a specific activity of 41.8 mCi mmol^?1 and radiochemical purity of 99.2% (HPLC). Copyright © 2002 John Wiley & Sons, Ltd.     

[14C] and [3H]‐labelling of Ragaglitazar: A dual acting PPARα and PPARγ agonist with hypolipidemic and anti‐diabetic activity

Currently, Ragaglitazar is being developed as a drug for the treatment of hyperglycaemia and hyperlipidemia in patients with type 2 diabetes. Here, we report the labelling of Ragaglitazar with carbon‐14 and tritium for in vivo and in vitro investigations. Two different carbon‐14 labelled as well as two different tritium labelled tracers of Ragaglitazar were synthesised. The carbon‐14 label was introduced from either ethyl bromo[2‐¹⁴C]acetate (5 steps/33% overall yield) or [U‐¹⁴C]phenoxazine (4 steps/48% overall yield). Tritium was incorporated either by catalytic tritiation of an alkene precursor followed by chiral HPLC separation (2 steps/17% overall yield) or by catalytic tritium–halogen exchange of an aryl bromide precursor (2 steps/68% overall yield). Copyright © 2003 John Wiley & Sons, Ltd.     

Fast and efficient tritium labelling of the nonsteroidal anti‐inflammatory drugs naproxen,tolmetin, and zomepirac

Fast and efficient tritium labelling of the nonsteroidal anti‐inflammatory drugs naproxen, tolmetin and zomepirac is reported. Naproxen along with its (R)‐enantiomer were labelled by catalytic tritium–halogen exchange of the corresponding 5‐bromo derivatives providing [³H]naproxen with a specific activity of 25.4 Ci/mmol. Tolmetin and zomepirac were labelled by the hydrogen isotope exchange reaction using Crabtree's catalyst. This provided [³H]tolmetin and [³H]zomepirac with specific activities of 80.8 and 64.3 Ci/mmol, respectively. All compounds were obtained in high radiochemical purity (>98%). Copyright © 2005 John Wiley & Sons, Ltd.     

Synthesis of C‐14 and C‐13, H‐2‐labeled IKK inhibitor: [14C] and [13C4,D3]‐N‐(6‐chloro‐7‐methoxy‐9H‐pyrido[3,4‐b]indol‐8‐yl)‐2‐methyl‐3‐pyridinecarboxamide

[¹⁴C]‐N‐(6‐Chloro‐7‐methoxy‐9H‐pyrido [3,4‐b]indol‐8‐yl)‐2‐methyl‐3‐pyridinecarboxamide (5B ), an IKK inhibitor, was synthesized from [¹⁴C]‐barium carbonate in two steps in an overall radiochemical yield of 41%. The intermediate, [carboxyl‐¹⁴C]‐2‐methylnicotinic acid, was prepared by the lithiation and carbonation of 3‐bromo‐2‐methylpyridine. [¹³C₄,D₃]‐N‐(6‐chloro‐7‐methoxy‐9H‐pyrido [3,4‐b]indol‐8‐yl)‐2‐methyl‐3‐pyridinecarboxamide (5C ) was synthesized from [1,2,3,4‐¹³C₄]‐ethyl acetoacetate and [D₄]‐methanol in six steps in an overall yield of 2%. [¹³C₄]‐2‐methylnicotic acid, was prepared by condensation of [¹³C₄]‐ethyl 3‐aminocrotonate and acrolein, followed by hydrolysis with lithium hydroxide. Copyright © 2006 John Wiley & Sons, Ltd.     

An overview of radio or stable isotope‐labeled cis‐neonicotinoid analogs

To support the metabolism and toxicology study of cis‐neonicotinoids, radio or stable isotope was introduced into different sites of the key intermediate 2‐chloro‐5‐((2‐(nitromethylene)imidazolidin‐1‐yl)methyl)pyridine (6‐Cl‐PMNI). [³H₂]‐ and [¹⁴C]‐label were successively prepared from initial materials NaB³H₄ and [¹⁴C]‐nitromethane, respectively. Similarly, [D₂]‐6‐Cl‐PMNI was prepared from NaBD₄ in four steps, with 52.6% overall isotopic yield, and dual‐labeled [D₂, ¹³C]‐target was obtained from NaBD₄ and [¹³C]‐nitromethane, affording overall isotopic yield of 42.5%. Moreover, [¹⁴C₂] was introduced from [U‐¹⁴C]‐ethylenediamine dihydrochloride in three steps, with a 58.3% overall chemical yield. Finally, typical labeled cis‐neonicotinoids paichongding and cycloxaprid were prepared and characterized. The methods were proved to have good generality in the synthesis of other cis‐neonicotinoids, and all results would be useful in metabolism studies of new cis‐neonicotinoids. Copyright © 2012 John Wiley & Sons, Ltd.     

Synthesis of isotope‐labeled HSP90 inhibitor: [13CD3] and [14C]‐TAK‐459

[¹³CD₃]‐TAK‐459 (1A), an HSP90 inhibitor, was synthesized from [¹³CD₃]‐sodium methoxide in three steps in an overall yield of 29%. The key intermediate [¹³CD₃]‐2‐methoxy‐6‐(4,4,5,5‐tetramethyl‐1,3,2‐dioxaborolan‐2‐yl)pyridine was synthesized in two steps from 2,6‐dibromopyridine and stable isotope‐labeled sodium methoxide. [¹⁴C]‐TAK‐459 (1B) was synthesized from [¹⁴C(U)]‐guanidine hydrochloride in five steps in an overall radiochemical yield of 5.4%. The key intermediate, [¹⁴C]‐(R)‐2‐amino‐7‐(2‐bromo‐4‐fluorophenyl)‐4‐methyl‐7,8‐dihydropyrido[4,3‐d]pyrimidin‐5(6H)‐one, was prepared by microwave‐assisted condensation.     

18F‐Labelled vorozole analogues as PET tracer for aromatase

One‐ and two‐step syntheses for the ¹⁸F‐labelling of 6‐[(S)‐(4‐chlorophenyl)(1H‐1,2,4‐triazol‐1‐yl)methyl]‐1‐(2‐[¹⁸F]fluoroethyl)‐1H‐benzotriazole, [¹⁸F]FVOZ, 1 and 6‐[(S)‐(4‐chlorophenyl)(1H‐1,2,4‐triazol‐1‐yl)methyl]‐1‐[2‐(2‐[¹⁸F]fluoroethoxy)ethyl]‐1H‐benzotriazole, [¹⁸F]FVOO, 2 were developed. In the two‐step synthesis, the nucleophilic fluorination step was performed by reacting (S)‐6‐[(4‐chlorophenyl)‐(1H‐1,2,4‐triazol‐1‐yl)methyl]‐1H‐benzotriazole (VOZ) with either the ¹⁸F‐labelled ethane‐1,2‐diyl bis(4‐methylbenzenesulfonate) or the oxydiethane‐2,1‐diyl bis(4‐methylbenzenesulfonate). The radiochemical yields were in the range of 9–13% after the 110–120 min total syntheses and the specific radioactivities were 175±7 GBq/µmol and 56 GBq/µmol for compounds 1 and 2, respectively. In the one‐step synthesis, the precursor 2‐{6‐[(4‐chlorophenyl)(1H‐1,2,4‐triazol‐1‐yl)methyl]‐1H‐1,2,3‐benzotriazol‐1‐yl}ethyl 4‐methylbenzenesulfonate (7) or 1‐[2‐(2‐bromoethoxy)ethyl]‐6‐[(4‐chlorophenyl)(1H‐1,2,4‐triazol‐1‐yl)methyl]‐1H‐benzotriazole (8) was directly labelled via an ¹⁸F nucleophilic substitution to give the corresponding tracer. The labelled compounds were obtained in 36–99% radiochemical yield after 75‐min syntheses. The specific radioactivities are 100 GBq/µmol for compound 1 and 80 GBq/µmol for compound 2. In vitro autoradiography using frozen rat brains illustrated specific binding in the medial amygdala, the bed nucleus of stria terminalis and the preoptic area, all of which corresponded well to the result of ¹¹C‐labelled vorozole. Copyright © 2008 John Wiley & Sons, Ltd.     

Synthesis of 1‐(2′‐deoxy‐2′‐fluoro‐β‐D‐arabinofuranosyl)‐[Methyl‐11C]thymine ([11C]FMAU) via a Stille cross‐coupling reaction with [11C]methyl iodide

1‐(2′‐deoxy‐2′‐fluoro‐β‐D‐arabinofuranosyl)‐[methyl‐¹¹C]thymine ([¹¹C]FMAU) [¹¹C]‐ 1 was synthesised via a palladium‐mediated Stille coupling reaction of 1‐(2′‐deoxy‐2′‐fluoro‐β‐D‐arabinofuranosyl)‐5‐(trimethylstannyl)uracil 2 with [¹¹C]methyl iodide in a one‐pot procedure. The reaction conditions were optimized by screening various catalysts and solvents, and by altering concentrations and reaction temperatures. The highest yield was obtained using Pd₂(dba)₃ and P(o‐tolyl)₃ in DMF at 130°C for 5 min. Under these conditions the title compound [¹¹C]‐ 1 was obtained in 28±5% decay‐corrected radiochemical yield calculated from [¹¹C]methyl iodide (number of experiments=7). The radiochemical purity was >99% and the specific radioactivity was 0.1 GBq/μmol at 25 min after end of bombardment. In a typical experiment 700–800 MBq of [¹¹C]FMAU [¹¹C]‐ 1 was obtained starting from 6–7 GBq of [¹¹C]methyl iodide. A mixed ¹¹C/¹³C synthesis to yield [¹¹C]‐ 1 /(¹³C)‐ 1 followed by ¹³C‐NMR analysis was used to confirm the labelling position. The labelling procedure was found to be suitable for automation. Copyright © 2002 John Wiley & Sons, Ltd.     

Synthesis of N,N‐diethyl‐4‐[phenyl‐(piperidin‐4‐ylidene)methyl]‐[carboxy‐14C]benzamide,a potent δ opioid receptor agonist

The synthesis of carbon‐14 labelled N,N‐diethyl‐4‐[phenyl‐(piperidin‐4‐ylidene)methyl]‐benzamide is described. The radioisotope is introduced via an aryllithium reaction with ¹⁴CO₂ to form the labelled acid, which is subsequently transformed into the amide. Copyright © 2002 John Wiley & Sons, Ltd.     

Expeditious syntheses of stable and radioactive isotope‐labeled anticonvulsant agent,JNJ‐26990990, and its metabolites

Syntheses of stable and radioactive isotope‐labeled anticonvulsant agent, JNJ‐26990990, that is, N‐(benzo[b]thien‐3‐ylmethyl)‐sulfamide and its metabolites are described. [¹³C¹⁵N]Benzo[b]thiophene‐3‐carbonitrile was first prepared by coupling of 3‐bromo‐benzo[b]thiophene with [¹³C¹⁵N]‐copper cyanide. The resultant [¹³C¹⁵N]benzo[b]thiophene‐3‐carbonitrile was reduced with lithium aluminum deuteride to give [¹³CD₂¹⁵N]benzo[b]thiophen‐3‐yl‐methylamine; which was then coupled with sulfamide to afford [¹³CD₂¹⁵N]‐N‐(benzo[b]thien‐3‐ylmethyl)‐sulfamide, the stable isotope‐labeled compound with four stable isotope atoms. Direct oxidation of [¹³CD₂¹⁵N]‐N‐(benzo[b]thien‐3‐ylmethyl)‐sulfamide with hydrogen peroxide and peracetic acid gave the stable isotope‐labeled sulfoxide and sulfone metabolites. On the other hand, radioactive ¹⁴C‐labeled N‐(benzo[b]thien‐3‐ylmethyl)‐sulfamide was prepared conveniently by sequential coupling of 3‐bromo‐benzo[b]thiophene with [¹⁴C]‐copper cyanide, reduction of the carbonitrile to carboxaldehyde, and reductive amination with sulfamide.     

Synthesis of 2H‐ and 3H‐labeled N‐cyclopropylmethyl‐7α‐[(R)‐1‐hydroxy‐1‐methyl‐3‐(2thienyl)‐propyl]‐6,14‐endoethano‐6,7,8,14‐tetrahydro nororipavine

A procedure for deuterium and tritium labeling of the titled compound, an analgesic agent, was developed. A secondary amine intermediate was acylated to an acylamide, then the carbonyl function was reduced by LiAlD₄ to yield the tertiary amine. In the tritium‐labeled synthesis, the process utilized a bromo‐substituted precursor, which was subsequently reduced with ³H₂ in the presence of a Pd/C catalyst. The labeled compounds were successfully applied in pharmacokinetic and pharmacological studies. Copyright © 2005 John Wiley & Sons, Ltd.